GOTHENBURG, Sweden, March 31, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced initial learnings from the 12-month...
Hence then, the article about cereno scientific reports favorable safety and tolerability after 12 months of cs1 treatment in pah from the expanded access program was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program )
Also on site :
- US charges alleged Iran-backed Kataib Hezbollah suspect – What we know
- Mercedes-Benz ‘willing’ to move into defense production – CEO
- Deadly virus outbreak kills 65 in DR Congo